您好,欢迎来到中国测试科技资讯平台!

首页> 《中国测试》期刊 >本期导读>雷公藤甲素温敏凝胶在大鼠体内的药代动力学研究

雷公藤甲素温敏凝胶在大鼠体内的药代动力学研究

1363    2020-11-24

免费

全文售价

作者:简锐, 廖昌军, 张全, 周爱民, 何阳森

作者单位:成都医学院药学院,四川 成都 610083


关键词:雷公藤甲素;液质联用;药代动力学;温敏凝胶


摘要:

建立LC-MS测定雷公藤甲素(TP)在大鼠体内血药浓度方法,并计算药代动力学参数。采用Agilent ZORBAX SB-C18(2.1 mm×50 mm,1.8 μm)色谱柱;流动相为甲醇(A)-水溶液(B)梯度洗脱;流量为0.3 mL/min;柱温35 ℃;进样量5 μL;多反应监测(MRM),离子化方式为负模式。SPF级SD大鼠18只,分为空白、温敏凝胶和溶液组,采用单剂量关节腔注射给药。给药后大鼠尾部静脉取血,LC-MS测定各时间点血浆药物浓度,DAS3.0计算药代动力学参数。在0.1~2.0 μg/L浓度范围内,TP与内标阿魏酸峰面积比值与浓度的线性关系良好。温敏凝胶和溶液组主要药动力学参数t1/2Tmax和AUC分别为:27.506 h、0.75 h、3.972 μg/L·h和16.967 h、0.5 h、2.283 μg/L·h。该方法可用于TP关节腔注射给药在大鼠体内药代动力学研究,为TP温敏凝胶制剂开发提供理论依据。


Research on pharmacokinetic of triptolide thermosensitive gel for rats
JIAN Rui, LIAO Changjun, ZHANG Quan, ZHOU Aiming, HE Yangsen
School of Pharmacy, Chengdu Medical College, Chengdu 610083, China
Abstract: This paper established a LC-MS method for determining the plasma concentration of triptolide (TP) in rats and to calculate pharmacokinetic parameters. An Agilent ZORBAX SB-C18 (2.1 mm×50 mm, 1.8 μm) chromatographic column was used; the mobile phase was methanol (A)-aqueous solution (B) gradient elution; the flow rate was 0.3 mL/min; the column temperature was 35 ℃ ; the injection volume 5 μL; Multiple Reaction Monitoring (MRM), ionization mode was negative mode. 18 SPF grade SD rats were divided into blank, temperature-sensitive gel and solution groups, and were administered by single-dose intra-articular injection. After administration, blood was collected from the tail vein of rats, and the plasma drug concentration was determined by LC-MS at each time point. DAS3.0 was used to calculate the pharmacokinetic parameters. Within the concentration range of 0.1-2.0 μg/L, the linear relationship between the ratio of TP and internal standard ferulic acid peak area and concentration was good. The main pharmacokinetic parameters t1/2, Tmax and AUC of the temperature-sensitive gel and solution groups were: 27.506 h, 0.75 h, 3.972 μg/L·h and 16.967 h, 0.5 h, 2.283 μg/L·h. This method can be used to study the pharmacokinetics of TP articular injection in rats, and provided a theoretical basis for the development of TP temperature-sensitive gel formulations.
Keywords: triptolide;LC-MS;pharmacokinetics;thermosensitive gel
2020, 46(11):48-52  收稿日期: 2020-04-18;收到修改稿日期: 2020-05-23
基金项目: 国家自然科学基金项目(81603045)
作者简介: 简锐(1996-),女,四川泸州市人,硕士研究生,专业方向为工业药剂学方向
参考文献
[1] 梁艳, 梅轶芳, 王艳丽, 等. 生物制剂在类风湿关节炎合并妊娠患者应用中的研究进展[J]. 中华内科杂志, 2016, 55(5): 400-402
[2] 范国涛, 谭俊铭. 类风湿关节炎累及颈椎的诊治进展[J]. 中国骨与关节损伤杂志, 2016, 31(3): 332-334
[3] 邵勤, 吴斌. 辅助性T细胞22/白细胞介素-22在类风湿关节炎中的研究进展[J]. 中华风湿病学杂志, 2016, 20(4): 274-278
[4] 张欣悦, 高永翔. JAK-STAT信号通路与类风湿关节炎相关研究进展[J]. 实用中医药杂志, 2016, 32(2): 196-198
[5] 常文静, 蔡辉. 类风湿关节炎患者骨重建标志物的研究进展[J]. 国际检验医学杂志, 2016, 36(9): 1236-1239
[6] LAHAYE C, TATAR Z, DUBOST J J, et al. Overview of biologic treatmentsin the elderly[J]. Joint Bone Spine, 2015, 82(3): 154-160
[7] 王鑫, 赵琴, 邓肇达, 等. 老年类风湿性关节炎治疗进展[J]. 中国骨伤, 2017, 30(6): 576-580
[8] HOU W, LIU B, XU H T. Triptolide: Medicinal chemistry, chemical biology and clinical progress[J]. European Journal of Medicinal Chemistry, 2019, 176(1): 378-392
[9] 陈伟, 逯卓卉, 韦登明, 等. 老年类风湿关节炎临床特征分析及中西医结合治疗进展[J]. 中国老年学杂志, 2016, 36(6): 1519-1521
[10] NI B, JIANG Z, HUANG X, et al. Male reproductive toxicity andtoxicokinetics of triptolide in rats[J]. Arzneimittelforschung, 2008, 58(12): 673-680
[11] 邰婷, 江振洲, 黄鑫, 等. 雷公藤甲素药代动力学研究进展[J]. 药学与临床研究, 2012(3): 229-235
[12] LAI K, HONG L H. Triptolide inhibits experimental choroidal neovascularization in mice by modulating focal inflammatory microenvironment through macrophages[J]. Visual Science, 2019, 60(9): 362-368
[13] 李欣宇, 肖磊, 朱照静. 地塞米松磷酸钠温度敏感原位凝胶释药与溶蚀行为的影响因素考察[J]. 中国医院药学杂志, 2010, 30(2): 142-146
[14] 陈美婉, 余思琴, 杨志文, 等. 纳米粒温敏喷雾凝胶的毒性试验研究[J]. 药物评价研究, 2011, 34(3): 174-178
[15] 危红华, 李莎莎, 韩腾飞, 等. 盐酸青藤碱关节腔注射用纳米粒温敏凝胶的制备及其性质考察[J]. 中草药, 2013, 4414: 1899-1904
[16] 王锐, 李建月, 杨婧. 川芎提取物接枝型鼻用温敏凝胶制备及药效学研究[J]. 上海中医药杂志, 2019, 53(6): 86-91
[17] ZHAO X Y , LIU X Y , ZHANG P C. Injectable peptide hydrogel as intraperitoneal triptolide depot for the treatment of orthotopic hepatocellular carcinoma[J]. Acta Phamarceutic Sinica, 2019, 9(5): 1050-1060